Biosimilar Road Bump: Teva Filgrastim's Complete Response Shows Even Full BLAs Can Stumble

FDA issued a complete response letter requesting "several items" from Teva to finish review of its biological license application.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet